Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Tuesday. The firm issued a hold rating on the stock.

A number of other research firms have also recently weighed in on EKSO. HC Wainwright decreased their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $0.72 on Tuesday. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.10. The company has a market cap of $15.84 million, a P/E ratio of -1.11 and a beta of 1.47. Ekso Bionics has a 12-month low of $0.70 and a 12-month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same period in the previous year, the company earned ($0.24) earnings per share. Research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC increased its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.